

ABSTRACT OF THE DISCLOSURE

A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered
5 directly to one or both putamen of a human in need of treatment thereof. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal brain catheters connected to an implantable pump.